KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Gains from Investment Securities: 2018-2025

Historic Gains from Investment Securities for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Sep 2025 value amounting to $613,000.

  • Aurinia Pharmaceuticals' Gains from Investment Securities fell 79.56% to $613,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year decrease of 82.17%. This contributed to the annual value of $12.0 million for FY2024, which is 87.25% down from last year.
  • According to the latest figures from Q3 2025, Aurinia Pharmaceuticals' Gains from Investment Securities is $613,000, which was down 90.11% from $6.2 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Gains from Investment Securities registered a high of $90.7 million during Q4 2023, and its lowest value of -$2.9 million during Q2 2021.
  • Its 3-year average for Gains from Investment Securities is $11.6 million, with a median of $3.9 million in 2023.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 143.45% in 2021, then spiked by 7,790.17% in 2023.
  • Aurinia Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at $3.1 million in 2021, then declined by 3.42% to $1.1 million in 2022, then soared by 7,790.17% to $90.7 million in 2023, then tumbled by 96.69% to $3.0 million in 2024, then crashed by 79.56% to $613,000 in 2025.
  • Its last three reported values are $613,000 in Q3 2025, $6.2 million for Q2 2025, and $8.9 million during Q1 2025.